There are over 100 FDA-approved drugs that contain the piperazine moiety.

Piperazine-based analogues may advantageously alter important pharmacokinetic properties when grafted onto molecular scaffolds.

In 2018, chemists showed that replacing a piperazine ring in the drug Olaparib with the spirodiamine analogue beneficially affected activity and reduced cytotoxicity of the parent compound.

We have designed and synthesized a library of piperazine analogues for drug design. More details about design and full list of compounds you can find at MedChem Highlights section of Enamine’s website.